I/WE CLAIM:

1. A compound of the formula



I

wherein,

R is $NH-(A)_n-CH_2OH$;



;



;



;



; or



A is *D* or *L* amino acid and n=1-10,

R_1 and R_2 are each independently, hydrogen, alkyl of 1-6 carbons atoms, hydroxyalkyl of 1-6 carbon atoms, or CO_2R_9,

R_3 is Ar,

R_4, R_5 and R_6 are each independently alkyl of 1-6 carbon atoms or hydroxyalkyl of 1-6 carbon atoms,
R_7 and R_8 are each independently hydrogen, cycloalkyl of 1-6 carbon atoms or hydroxycycloalkyl of 3-16 carbon atoms, and
R_9 is alkyl of 1-6 carbon atoms,
R_{10} is alkyl of 1-10 carbon atoms and
R_{11} is cycloalkoxyalkyl of 3-10 carbon atoms.

and wherein R and said compound of formula I are linked through a carbamate ester linkage.

2. The compound as claimed in claim 1 wherein R is selected from structures 7a-7y.

3. A pharmaceutical composition comprising the compound as claimed in claim 1 or 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for use in treating cell proliferation disorders.

4. A method for treating a cell proliferation disorder comprising administering the pharmaceutical composition as claimed in claim 3 to a patient in need thereof in an amount sufficient to reduce cell proliferation.

5. The method as claimed in claim 4 wherein said cell proliferation disorder is selected from cancer, hyperplasia, psoriasis and hyperproliferative vascular disease.

6. The method as claimed in claim 5 wherein said hyperproliferative vascular disease is restenosis.

7. The method as claimed in claim 5 or 6 wherein said composition is released from a carrier, said carrier being implanted at a desired location within said patient.

8. The method as claimed in claim 7 wherein said carrier is implanted using a vascular guiding means.

9. The method as claimed in claim 8 wherein said vascular guiding means is a cathether.

10. A stent coated with the compound of claim 1 or 2 or the composition of claim 3.

11. The stent as claimed in claim 10 wherein said compound of claim 1 or composition of claim 2 is comprised within a coating composition.

12. The stent as claimed in claim 10 or 11 for treating a hyperproliferative vascular disease.

13. The stent as claimed in claim 12 wherein said hyperproliferative vascular disease is restenosis.

14. A pharmaceutical composition comprising the compound as claimed in claim 1 or 2, or a pharmaceutically acceptable salt thereof, and a

pharmaceutically acceptable carrier for use as an immunosuppressant.

15. A method for treating an immunological condition comprising administering the pharmaceutical composition as claimed in claim 14 to a patient in need thereof in an amount sufficient to suppress the immune system.

16. The method as claimed in claim 15 wherein said immunological disorder is selected from autoimmune disease and host-graft disease.

17. A process for the preparation of the compound of claim 1 or 2 comprising reacting 42-O-(4-Nitrophenoxycarbonyl)rapamycin and an amino acid or a peptide or an amino alcohol under basic conditions.

18. The process as claimed in claim 17 wherein said base is pyridine.